BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Amundi

Key Points

• Amundi increased its BioMarin Pharmaceutical stake by 37.8% in the second quarter, acquiring 71,246 additional shares for a total holding of 259,782 shares valued at approximately $14.9 million. Institutional investors collectively own 98.71% of BMRN.
• BioMarin reported quarterly earnings of $1.20 per share, beating estimates of $0.95, while revenue rose 20% year over year to $989.7 million. The company provided fiscal 2026 EPS guidance of $4.90–$5.10.
• Analyst sentiment remains positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $89.17, well above its reported opening price of $65.68.

Amundi lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 37.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 259,782 shares of the biotechnology company's stock after acquiring an additional 71,246 shares during the period. Amundi owned 0.13% of BioMarin Pharmaceutical worth $14,865,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CIBC Private Wealth Group LLC grew its stake in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after buying an additional 179 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in BioMarin Pharmaceutical in the second quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd purchased a new position in BioMarin Pharmaceutical in the third quarter worth approximately $40,000. Parallel Advisors LLC increased its stake in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 295 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new stake in BioMarin Pharmaceutical in the second quarter valued at $56,000. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Price Performance

Shares of BMRN opened at $65.68 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The firm's 50 day moving average price is $63.30 and its 200 day moving average price is $58.50. The company has a market cap of $12.71 billion, a P/E ratio of 177.51, a PEG ratio of 0.47 and a beta of 0.24. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million during the quarter, compared to analysts' expectations of $932.03 million. During the same quarter last year, the company posted $1.44 EPS. The firm's revenue was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts forecast that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BMRN shares. Jefferies Financial Group raised their price objective on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a "buy" rating in a research report on Monday, August 31st. Piper Sandler lifted their price target on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Tuesday, September 1st. BMO Capital Markets assumed coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, August 19th. They issued an "outperform" rating and a $98.00 price objective on the stock. Wall Street Zen raised shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Canaccord Genuity Group lifted their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a "buy" rating in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $89.17.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin's marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.